123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Colevas, Dimitrios; Misiukiewicz, Krzysztof; Pearson, Alexander T.; Fayette, Jérôme; Bauman, Jessica R.; Cupissol, Didier; Sâada-Bouzid, Esma; Adkins, Douglas R.; Marie, Delphine; Cornen, Stéphanie; Pèlegrin, André; Carrette, Florent; Rotolo, Federico; Chammard, A. Boyer; Cohen, Romain

doi:10.1016/j.annonc.2021.10.142

Cited by 10 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monalizumab is an ICI active on NKG2A and thus able to activate anti-tumor activity of NK cells. This agent was evaluated in combination with cetuximab and durvalumab in a non-randomized, single-arm phase II trial involving treatment-naïve patients with recurrent or metastatic SCCHN (NCT02643550); in this study, the combination including monalizumab was characterized by acceptable safety profile and promising antitumor activity [ 66 ]. With regards to NSCLC, the activity of monalizumab was recently explored in the COAST trial (NCT03822351), an open-label phase II, randomized study in which patients who had been treated with chemo-radiation for inoperable stage III NSCLC were randomized to receive maintenance with durvalumab alone, the current standard of care, or durvalumab in combination with either oleclumab (an anti-CD73 agent) or monalizumab.…”

Section: Nk Cell Targeting To Improve Anti-tumor Responsementioning

confidence: 99%

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy

Grottoli

Carrega

Zullo

et al. 2022

Cancers

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) immunotherapy has represented a breakthrough in cancer treatment. Clinical use of ICIs has shown an acceptable safety profile and promising antitumor activity. Nevertheless, some patients do not obtain clinical benefits after ICIs therapy. In order to improve and cure an increasing number of patients, the field has moved toward the discovery of new ICIs expressed by cells of innate immunity with an elevated inherent antitumor activity, such as natural killer cells. This review will focus on the recent findings concerning the role of classical and non-classical immune checkpoint molecules and receptors that regulate natural killer cell function, as potential targets, and their future clinical application.

show abstract

Section: Nk Cell Targeting To Improve Anti-tumor Responsementioning

confidence: 99%

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy

Grottoli

Carrega

Zullo

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…70 Durvalumab was added in an expansion cohort, with promising activity with acceptable safety profile and lower discontinuation rate with an ORR of 33% (40 patients) and median OS of 15 months. 71 A phase III study is ongoing (NCT04590963).…”

Section: Other Immunotherapies and Immunotherapy Combinationsmentioning

confidence: 99%

Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges

Wise‐Draper

Bahig

Karivedu

et al. 2022

American Society of Clinical Oncology Educational Book

View full text Add to dashboard Cite

Management of metastatic head and neck squamous cell carcinoma is evolving as new systemic therapies have led to improvements in survival, and as advances in locoregional therapy and the increased numbers of patients with HPV-associated cancers who develop oligometastases raise the possibility of ablation of limited numbers of metastases. We review the data regarding first-line immunotherapy in PD-L1–expressing metastatic head and neck squamous cell carcinoma, the experience with aggressive local management of oligometastases, and promising novel immunotherapies, targeted therapies, and HPV-specific treatments. For patients with metastatic head and neck squamous cell carcinoma that is PD-L1 expressing, first-line systemic therapy is pembrolizumab or pembrolizumab with chemotherapy. Inclusion of chemotherapy is associated with higher objective response proportion in all biomarker subgroups and may have a greater impact on survival in HPV-associated cancers. For patients with oligometastatic disease, particularly when metastases are metachronous, current evidence supporting the role of local ablation is limited to a small number of retrospective studies. Based on retrospective data, patients with a smaller number of metastases, lung metastases, and/or virally associated head and neck squamous cell carcinoma are most likely to benefit from an aggressive ablative approach. Additionally, we review emerging evidence for targeted therapy in metastatic head and neck squamous cell carcinoma, including with agents that inhibit mutant HRAS or NOTCH1, or overexpressed EGFR. Studies of antiangiogenic agents in combination with immune checkpoint blockade, and combination immunotherapy, are also under study.

show abstract

“…The cohort was expanded and durvalumab was added. This resulted in an overall response rate of 33% and a median overall survival of 15 months [ 118 ]. The study has progressed to phase III (NCT04590963).…”

Section: Checkpoint Regulators and Combination Therapymentioning

confidence: 99%

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers

Ettl

Grube

Schulz

et al. 2022

Cancers

View full text Add to dashboard Cite

Recently, considerable progress has been achieved in cancer immunotherapy. Targeted immune checkpoint therapies have been established for several forms of cancers, which resulted in a tremendous positive impact on patient survival, even in more advanced tumor stages. With a better understanding of cellular responses to immune checkpoint therapies, it will soon be feasible to find targeted compounds which will make personalized medicine practicable. This is a great opportunity, but it also sets tremendous challenges on both the scientific and clinical aspects. Head and neck tumors evade immune surveillance through various mechanisms. They contain fewer lymphocytes (natural killer cells) than normal tissue with an accumulation of immunosuppressive regulatory T cells. Standard therapies for HNSCC, such as surgery, radiation, and chemotherapy, are becoming more advantageous by targeting immune checkpoints and employing combination therapies. The purpose of this review is to provide an overview of the expanded therapeutic options, particularly the combination of immune checkpoint inhibition with various conventional and novel therapeutics for head and neck tumor patients.

show abstract

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Cited by 10 publications

References 0 publications

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy

Current Therapy for Metastatic Head and Neck Cancer: Evidence, Opportunities, and Challenges

Checkpoint Inhibitors in Cancer Therapy: Clinical Benefits for Head and Neck Cancers

Contact Info

Product

Resources

About